|
1. BIOLOGIE
|
|
|
Priorities for the next 10 years of human microbiome research [Nature]
|
|
|
|
|
|
I think that interventions that could help to treat conditions such as diabetes, cancer and autoimmune diseases will be discovered only if we move beyond species catalogues and begin to understand the complex and mutable ecological and evolutionary relationships that microbes have with each other and with their hosts.
|
|
|
|
|
|
|
1.4 BIOLOGIE - TECHNOS
|
|
|
Genomics institute to close world-leading animal facility [Nature]
|
|
|
|
|
|
The institute says that the closure, announced to staff on 16 May, is a consequence of a move towards using alternative technologies, such as cell lines and organoids — 3D biological structures that can be grown in a dish — in genetics research, instead of animals.
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.16 TRAITEMENTS - CHIRURGIE
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
Global Oncology Trends 2019 [Iqvia]
|
|
|
|
|
|
Despite high levels of pipeline activity, oncology remains one of the most challenging areas for research and development, facing significant risk of failure and long development times. The composite success rate for phase transitions fell to 8.0% in 2018 from 11.7% in 2017, and clinical trial duration remains higher for oncology trials than other disease areas.
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-29 May 2019 [EMA]
|
|
|
|
|
|
The applicant for Doxolipad (doxorubicin) requested a re-examination of the Committee's negative opinion adopted at the January 2019 meeting. After considering the grounds for this request, the CHMP re-examined the initial opinion and confirmed its previous recommendation to refuse the granting of a marketing authorisation for this medicine, which was intended for the treatment of breast and ovarian cancer.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
|
Overall cancer death rates falling in U.S., NIH reports [UPI]
|
|
|
|
|
|
Between 2011 and 2015, the report showed that incidences of cancer went down by 0.7 percent for men and increased 1.3 percent for women each year. From 2012 to 2016, the average annual cancer death rate for every 100,000 people was 22.8 for men and 27.1 for women.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
|